AI could replace biopsies for bladder cancer testing

NCT ID NCT07454941

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study enrolls 4,000 people with urothelial carcinoma to test whether artificial intelligence can predict HER2 expression using MRI scans and pathology images. The goal is to create a model that accurately assesses HER2 status without needing invasive biopsies, helping doctors decide on targeted therapy faster. Researchers will also use AI to diagnose tumor type, grade, and invasiveness from pre-treatment images.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Artificial intelligence model
What this could lead to
If successful, this AI model could quickly and accurately predict HER2 status from MRI scans, helping doctors choose the right targeted therapy without needing a biopsy.
What could go wrong
This is an early-stage model validation study, not a treatment trial. The AI may not be accurate enough in real-world settings, and results may not apply to all patients or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIAGNOSTIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences Beijing

    Beijing, Chaoyang District, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.